Alnylam enters $500.0 million revolving credit facility with Bank of America as agent
Alnylam Pharmaceuticals entered a $500.0 million revolving credit agreement on September 30, 2025, with Bank of America, N.A. as administrative agent. The facility is secured by substantially all company assets, subject to customary exceptions, and carries financial covenants on leverage and interest coverage. The filing describes a credit line available for working capital and general corporate purposes, not a drawn loan.
Key points
- Revolving credit facility of $500.0 million, including a $150.0 million letter of credit sublimit
- Matures September 30, 2030, subject to a springing maturity tied to certain debt levels
- Interest at term SOFR plus a margin of 1.50% to 2.50%, based on the Total Leverage Ratio; commitment fee of 0.20% to 0.35% on unused amounts
- Covenants require a Total Net Leverage Ratio at or below 3.75:1.00 and a Consolidated Interest Coverage Ratio at or above 3.00:1.00
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 03, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.